Abstract

A SINGLE CASE STUDY ON THE EFFECT OF USHEERASAV IN THE MANAGEMENT OF ASRIGDARA W.S.R. TO MENORRHAGIA

Dr. Neha Rai*, Dr. Priti Singh Verma

Abstract

Background: Asrigdara is a common gynaecological disorder characterised by excessive or prolonged menstrual bleeding, significantly impacting the quality of life of women in their reproductive years. It is described in Ayurvedic classics as a Raktadoshaja Vikara manifesting as pitta Avritaapana vayu. Contemporary medicine correlates this condition with menorrhagia, defined as cyclic bleeding with blood loss exceeding 80 ml or duration beyond 7 days. Usheerasav, a fermented polyherbal formulation, is traditionally indicated in Raktapitta and bleeding disorders due to its Sheeta (cooling), Kashaya (astringent) and Raktastambhak (haemostatic) properties. Case Presentation: A 32‑year‑old married female, para‑2, presented with complaints of heavy menstrual bleeding lasting 8–9 days per cycle, requiring 22–24 sanitary pads per cycle, with passage of clots, and intermenstrual interval of 21 days for the past 6 months. She also reported associated symptoms of generalised weakness, fatigue, and low backache. Her haemoglobin was 9.2 g/dL. Ultrasonography of the lower abdomen revealed no structural abnormalities. Based on the presenting features, the condition was diagnosed as Asrigdara (menorrhagia). Intervention: The patient was administered Usheerasav 20 ml with 20 ml of water as Anupana, twice daily after meals (Paschchatbhakta) for 60 days. Assessment: Clinical assessment was done at baseline, on the 30th day, 60th day, and one month after completion of treatment using subjective parameters (number of pads used per cycle, duration of bleeding, amount of flow, intermenstrual period) and objective parameter (haemoglobin estimation). Results: At the end of 60 days of treatment, the patient showed marked improvement: pad usage reduced from 22–24 to 12–14 per cycle, bleeding duration decreased from 8–9 days to 5 days, flow became moderate without clots, and the intermenstrual interval normalised to 28 days. Haemoglobin improved from 9.2 g/dL to 11.4 g/dL. No adverse drug reactions were observed. Conclusion: Usheerasav demonstrated significant efficacy in the management of Asrigdara (menorrhagia) by reducing menstrual blood loss, normalising bleeding duration and cycle regularity, and improving haemoglobin levels. The drug was found to be safe and well‑tolerated.

Keywords: Asrigdara, Menorrhagia, Usheerasav, Abnormal Uterine Bleeding, Raktapitta.